GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021

/PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...

Related Keywords

Switzerland ,David Castaneda ,Beverly Hills ,Exchange Commission ,University Of Minnesota ,Gt Biopharma Inc ,European Society For Medical Oncology ,Oncology Io Congress ,European Society ,Medical Oncology ,Poster Display Title ,Tri Specific Killer Engager ,Annual Report ,Quarterly Report ,Securities Act ,Relations Contacts ,Investor Relations Consultant ,Gt Biopharma ,Nc ,